目的探讨超选择性眼动脉溶栓治疗视网膜中央动脉阻塞(CRAO)的临床疗效。方法回顾性研究2022年1月至2023年7月在潍坊医学院附属医院眼科就诊的CRAO患者,选择发病时间1~3天的CRAO患者138例。其中,86例患者拒绝溶栓治疗,选择采用传统治疗,分为对照组;52例患者采用超选择性眼动脉溶栓治疗,被归类为观察组。记录患者在发病后第4天接受传统模式治疗的患者的视力和术后第1天接受超选择性眼动脉溶栓治疗的患者的视力,比较两组患者不同治疗方式后的视力改善情况。结果对照组,77例(89.5%)患者视力无改善,9人(10.5%)有所改善,0(0.0%)有显著改善,总改善9例(10.5%);观察组,18例(34.6%)接受治疗的患者视力无改善,21人(40.4%)有所改善,13(25.0%)有显著改善,总改善为34(65.4%)。观察组的治疗总改善率为65.4%,显著高于对照组的10.5%,差异有统计学意义(P<0.05)。结论超选择性眼动脉溶栓治疗CRAO临床疗效确切,促进患者视力的改善,并且具有很高的安全性。
BACKGROUND: The aim of the study was to investigate the clinical efficacy of superselective ophthalmic artery thrombolysis for central retinal artery occlusion (CRAO).
METHODS: Retrospective study of CRAO patients who attended the Department of Ophthalmology of Affiliated Hospital of Weifang Medical University from January 2022 to July 2023, 138 CRAO patients with onset time of 1-3 days were selected for the study. Among them, 86 patients refused thrombolytic treatment and chose to adopt traditional treatment, which was categorized as the control group; 52 patients adopted superselective ophthalmic artery thrombolytic treatment, which was categorized as the observation group. The visual acuity of the patients treated with traditional modality on the 4th day after the onset of the disease and the visual acuity of the patients treated with superselective ophthalmic artery thrombolysis on the 1st postoperative day were recorded, and the visual acuity improvement after different modalities of treatment was compared between the two groups.
RESULTS: In the control group, 77 (89.5%) of the treated patients had no improvement in visual acuity, 9 (10.5%) had improvement, 0 (0.0%) had significant improvement, and the total improvement was 9 (10.5%); in the observation group, 18 (34.6%) of the treated patients had no improvement in visual acuity, 21 (40.4%) had improvement, 13 (25.0%) had significant improvement, and the total improvement was 34 (65.4%). The total improvement rate of treatment in the observation group was 65.4%, which was significantly higher than the 10.5% in the control group, and the difference was statistically significant (p < 0.05).
CONCLUSIONS: Superselective ophthalmic artery thrombolysis for patients with CRAO is clinically effective, promotes improvement in patient vision, and has a high safety profile.